We found that the clinical, radiological, and molecular features of IDH-wt and IDH-mut LTS were significantly different and the two subtypes of LTS showed distinct PFS and post-progression survival (PPS), which can help the physicians to better understand GBM and may contribute to making more tailored treatment decisions for patients. This evidence concerns the gene IDH1 and glioblastoma.